What is CJC-1295 Without DAC and its mechanism of action?

CJC-1295 Without DAC (also known as Modified GRF 1-29 or Mod GRF 1-29) is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of GHRH with four strategic amino acid substitutions that dramatically enhance stability and potency. Unlike CJC-1295 With DAC (Drug Affinity Complex), the 'Without DAC' version lacks the lysine-maleimidoproprionic acid modification, resulting in a shorter half-life (approximately 30 minutes) that mimics natural pulsatile growth hormone secretion patterns. CJC-1295 Without DAC's mechanism involves: (1) GHRH receptor agonism - binding and activating GHRH receptors (GHRH-R) on pituitary somatotroph cells, triggering Gs protein-coupled signaling cascades involving adenylyl cyclase activation, cAMP generation, and protein kinase A (PKA) activation leading to growth hormone gene transcription and GH vesicle exocytosis, (2) Pulsatile GH release - the short half-life produces discrete GH pulses mimicking physiological circadian GH secretion patterns, avoiding sustained non-physiological GH elevation, (3) GHRP synergy - when combined with growth hormone secretagogues (GHRP-6, GHRP-2, Ipamorelin), produces supraadditive GH release through dual cAMP and calcium signaling pathway convergence, (4) Enhanced stability - four amino acid substitutions (Tyr1→DAla2, Ala8→Gln15, Ala15→Leu27, Leu27→Ala) increase resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and extend biological half-life from 7 minutes (native GHRH) to ~30 minutes, and (5) IGF-1 upregulation - pulsatile GH secretion stimulates hepatic insulin-like growth factor-1 (IGF-1) production through JAK-STAT signaling. This pulsatile GHRH analog makes CJC-1295 Without DAC invaluable for studying physiological GH secretion patterns, circadian GH rhythms, GHRH receptor pharmacology, and GH-IGF-1 axis regulation in laboratory endocrine research.

What research applications benefit from CJC-1295 Without DAC?

CJC-1295 Without DAC excels in pulsatile growth hormone secretion research mimicking natural GH pulses, GHRH receptor (GHRH-R) pharmacology and signaling pathway studies, circadian GH rhythm investigations examining ultradian and circadian patterns, synergistic GH release mechanisms when combined with GH secretagogues (GHRP-6, GHRP-2, Ipamorelin, Hexarelin), comparative GHRH analog research (CJC-1295 Without DAC vs Sermorelin vs Tesamorelin vs CJC-1295 With DAC), GH-IGF-1 axis studies examining growth factor dynamics, cAMP-PKA signaling pathway research in somatotroph cells, age-related GH decline and pulsatile secretion pattern alterations, metabolic research including glucose homeostasis and lipid metabolism, peptide stability and structure-activity relationship (SAR) studies examining effects of amino acid substitutions on protease resistance, muscle growth and protein synthesis pathway investigations, bone metabolism and mineralization research, and combination secretagogue protocols optimizing dual-pathway GH stimulation. The pulsatile secretion profile makes CJC-1295 Without DAC particularly valuable for studying physiological GH patterns, investigating somatopause (age-related GH decline), and examining the importance of pulsatile vs sustained GH elevation in metabolic and growth-promoting effects. Ideal for endocrinology laboratories, neuroendocrine research, aging biology, and growth factor physiology studies.

What purity and quality standards does your CJC-1295 Without DAC meet?

Our CJC-1295 Without DAC exceeds >98% purity verified by HPLC analysis with comprehensive quality control. Each batch undergoes: mass spectrometry molecular weight confirmation for the 29-amino acid modified GHRH analog structure (molecular weight ~3367 Da), peptide sequence verification confirming the four key amino acid substitutions (Tyr1→DAla2, Ala8→Gln15, Ala15→Leu27, Leu27→Ala) that differentiate Modified GRF 1-29 from native GHRH, verification of absence of DAC (Drug Affinity Complex) modification confirming this is the short-acting 'Without DAC' variant not the long-acting 'With DAC' version, bioactivity testing using GH secretion assays from pituitary cell cultures demonstrating dose-dependent GH stimulation typically 3-6x baseline (higher when combined with GHRPs), GHRH receptor binding assays confirming receptor affinity, cAMP accumulation assays validating Gs-coupled signaling pathway activation, endotoxin screening ( 98% purity ensures reproducible GHRH receptor activation and pulsatile GH-releasing effects without interference from degradation products, incorrect sequences, or the DAC modification. All analytical methods validate both chemical identity (correct amino acid sequence with four substitutions, absence of DAC) and biological activity (GHRH-R activation, cAMP signaling, GH secretion) - essential for reliable pulsatile GH physiology research distinguishing this short-acting Modified GRF 1-29 from the long-acting CJC-1295 With DAC variant.

How does CJC-1295 Without DAC differ from CJC-1295 With DAC?

CJC-1295 Without DAC and With DAC share the same core modified GHRH(1-29) peptide sequence but differ critically in the presence/absence of the Drug Affinity Complex (DAC) modification, resulting in dramatically different pharmacokinetics and GH secretion profiles: (1) Half-life - Without DAC has ~30 minute half-life producing pulsatile GH secretion mimicking physiological patterns, while With DAC has ~8 day half-life from albumin binding via the DAC modification producing sustained non-pulsatile GH elevation, (2) GH secretion pattern - Without DAC produces discrete GH pulses when administered (ideal for studying ultradian GH rhythms), while With DAC causes sustained basal GH elevation without distinct pulses, (3) Physiological relevance - Without DAC mimics natural pulsatile GH secretion important for metabolic effects and growth, while With DAC creates non-physiological sustained GH elevation not seen endogenously, (4) Dosing frequency - Without DAC typically requires multiple daily administrations in research models to simulate circadian GH patterns, while With DAC provides sustained GH stimulation from single weekly administration, (5) GHRP synergy - Without DAC combines powerfully with GHRPs (GHRP-6, Ipamorelin) for acute supraadditive GH pulses, while With DAC shows blunted synergy due to continuous GHRH receptor occupancy, and (6) Research applications - Without DAC is preferred for studying pulsatile GH physiology, circadian rhythms, acute GH release mechanisms, and combination protocols, while With DAC is used for investigating sustained GH effects, long-term metabolic studies, and chronic GH elevation models. Choose Without DAC when research priorities include physiological GH patterns, pulsatility, GHRP combinations, or acute GH response studies. Choose With DAC for sustained GH elevation, reduced dosing frequency, or chronic exposure research models.

How should CJC-1295 Without DAC be stored and reconstituted?

Store lyophilized CJC-1295 Without DAC at -20°C in original sealed vials for 24+ months stability. The modified 29-amino acid peptide structure provides good chemical stability when lyophilized and frozen. Reconstitute by adding bacteriostatic water (0.9% benzyl alcohol) or sterile saline slowly down the vial wall, then gently swirl (never shake to avoid aggregation) until completely dissolved at typical concentration 1-5 mg/mL. Refrigerate reconstituted solution at 2-8°C and use within 14 days to maintain optimal GHRH receptor-activating and GH-releasing bioactivity. The short half-life (~30 minutes) means biological activity diminishes rapidly in vivo after administration, but the reconstituted peptide solution itself remains stable for 14 days refrigerated. Avoid multiple freeze-thaw cycles which can degrade the peptide structure. For studies requiring multiple daily dosing to simulate pulsatile GH patterns, aliquot reconstituted solution into single-use sterile vials immediately after reconstitution to prevent repeated temperature cycling and contamination. Store aliquots at 2-8°C for short-term use. Proper storage ensures consistent GHRH receptor activation, reproducible pulsatile GH secretion, and reliable synergy when combined with GHRPs in dual-pathway GH stimulation research protocols. The amino acid substitutions provide enhanced stability vs native GHRH, but proper handling is still essential for maintaining bioactivity in research applications.

What bioactivity assays validate CJC-1295 Without DAC's GH-releasing effects?

Beyond chemical purity verification (HPLC/mass spec confirming correct sequence and absence of DAC), we perform comprehensive bioactivity assays: (1) GH secretion assays - measuring growth hormone release from primary rat or mouse pituitary cells, immortalized somatotroph cell lines (GH3, GH4C1), or pituitary explant cultures treated with CJC-1295 Without DAC vs vehicle controls, quantifying GH via ELISA or RIA, demonstrating dose-dependent GH secretion typically 3-6x baseline (higher with GHRP co-treatment), (2) GHRH receptor binding assays - competitive binding displacement of radiolabeled GHRH from recombinant GHRH receptors, confirming receptor affinity enhanced vs native GHRH due to amino acid substitutions, (3) cAMP accumulation assays - measuring cyclic AMP generation in GHRH-R-expressing cells using ELISA or fluorescence-based assays, validating Gs-coupled signaling pathway activation and demonstrating potency vs native GHRH, (4) PKA activation assays - phosphorylation of PKA substrates (CREB, etc.) downstream of cAMP-PKA pathway, confirming signal transduction, (5) Synergy assays - testing CJC-1295 Without DAC + GHRPs (Ipamorelin, GHRP-6) showing supraadditive GH release (>8-12x baseline) from dual cAMP and calcium pathway convergence, and (6) Stability assays - comparing CJC-1295 Without DAC vs native GHRH in presence of DPP-4 enzyme or plasma, demonstrating enhanced protease resistance from amino acid substitutions. Certificate of Analysis includes GH secretion data (fold-increase vs control, EC50 values, synergy quantification with GHRPs) ensuring physiologically relevant GHRH receptor-mediated GH-stimulating bioactivity. These functional assays confirm CJC-1295 Without DAC's GHRH-R activation, cAMP-PKA signaling, pulsatile GH release capability, and synergistic potential with GHRPs - validating its utility for pulsatile GH physiology research.

What dosage variants and pricing are available for CJC-1295 Without DAC?

We offer 2 specification options to accommodate different research scales: CND5 (5mg per 10-vial kit) and CND10 (10mg per 10-vial kit). Pricing structure: CND5 at $150/kit (1 kit), $145/kit (20+ kits), $140/kit (50+ kits). CND10 at $240/kit (1 kit), $230/kit (20+ kits), $220/kit (50+ kits). Bulk orders receive ~5-10% discount at 20+ kits, ~7-13% at 50+ kits. The concentration range supports pilot pulsatile GH secretion studies (5mg ideal for initial dose-response characterization, screening experiments, and synergy studies with GHRPs) through extensive multi-week circadian GH research requiring multiple daily dosing (10mg for chronic pulsatile secretion studies, large animal models, combination protocol optimization). The pricing reflects complex peptide synthesis (29 amino acids with four specific substitutions requiring careful verification of absence of DAC modification) while maintaining >98% pharmaceutical-grade purity standards. CJC-1295 Without DAC is more expensive than simpler hexapeptides (like GHRP-6) but less expensive than the long-acting With DAC variant. For large-scale or multi-year GH physiology projects, comparative GHRH analog research programs, combination secretagogue studies, or institutional core facility procurement, contact via WhatsApp to discuss custom quantity requirements and volume pricing. Research-grade quality enabling reliable pulsatile GH investigation for academic and pharmaceutical laboratories worldwide.

How does CJC-1295 Without DAC activate GHRH receptors to stimulate GH?

CJC-1295 Without DAC (Modified GRF 1-29) binds growth hormone-releasing hormone receptors (GHRH-R) on pituitary somatotroph cells, triggering Gs protein-coupled signaling cascades: (1) Receptor binding - the modified 29-amino acid sequence binds GHRH-R with high affinity (enhanced vs native GHRH due to four stabilizing amino acid substitutions preventing rapid degradation), (2) Gs protein activation - ligand binding causes conformational change activating Gs proteins, (3) Adenylyl cyclase activation - Gs stimulates adenylyl cyclase (AC) converting ATP to cyclic AMP (cAMP) second messenger, (4) cAMP-PKA pathway - elevated cAMP activates protein kinase A (PKA), (5) CREB phosphorylation - PKA phosphorylates cAMP response element-binding protein (CREB) and other transcription factors, (6) GH gene transcription - phospho-CREB binds cAMP response elements (CREs) in the growth hormone gene promoter, increasing GH mRNA transcription, (7) Acute GH secretion - PKA also promotes calcium channel opening and phosphorylation of proteins facilitating GH vesicle fusion and exocytosis for immediate GH release, and (8) GHRP synergy - when co-administered with GHRPs (which activate Gq-coupled GHS-R1a triggering calcium release), the convergence of cAMP-PKA and calcium signaling pathways produces supraadditive GH secretion exceeding either pathway alone. The short ~30 minute half-life means GH pulses rise and fall discretely, mimicking physiological pulsatile secretion. Systemically, released GH stimulates hepatic IGF-1 production through JAK-STAT signaling. Researchers use CJC-1295 Without DAC to dissect GHRH-R signaling, study cAMP-PKA pathway dynamics, investigate synergistic mechanisms with calcium-mobilizing GHRPs, examine pulsatile GH patterns, and understand physiological growth hormone regulation in endocrine research models.

Can CJC-1295 Without DAC be combined with GH secretagogues for synergistic effects?

Absolutely! CJC-1295 Without DAC + GHRP combinations represent the gold standard for maximizing pulsatile GH release in research models through dual-pathway synergy. Mechanistically: CJC-1295 Without DAC activates GHRH receptors via Gs-coupled cAMP-PKA signaling, while GHRPs (Ipamorelin, GHRP-6, GHRP-2, Hexarelin) activate GHS-R1a (ghrelin receptors) via Gq-coupled calcium mobilization. When combined, cAMP and calcium pathways converge synergistically on GH secretory machinery, producing supraadditive GH release - typically 8-15x baseline compared to 3-6x for CJC-1295 Without DAC alone or 4-8x for GHRPs alone. Common research combinations: (1) CJC-1295 Without DAC + Ipamorelin - most selective combination with minimal off-target effects (no appetite stimulation, no cortisol/prolactin elevation), ideal for pure GH release studies, (2) CJC-1295 Without DAC + GHRP-6 - combines pulsatile GH with appetite stimulation, useful for cachexia models and metabolic research, (3) CJC-1295 Without DAC + GHRP-2 - balanced GH release with moderate ghrelin effects, and (4) CJC-1295 Without DAC + Hexarelin - very potent GH release plus potential cardioprotective effects for specialized research. The short half-life of CJC-1295 Without DAC preserves synergistic pulsatile patterns (vs With DAC which shows blunted synergy from continuous receptor occupancy). Research applications include: optimizing GH pulse amplitude and frequency, investigating cross-talk between cAMP and calcium signaling pathways, studying pituitary somatotroph maximal secretory capacity, examining age-related changes in synergistic responsiveness, and developing optimal combination secretagogue protocols. Timing is critical - simultaneous administration produces maximal synergy. The combination approach reveals mechanisms impossible to study with single-pathway stimulation alone.

What documentation and shipping support CJC-1295 Without DAC research?

We ship CJC-1295 Without DAC in lyophilized form with cold pack insulation in sealed, insulated packaging to minimize temperature exposure during international transit. The modified 29-amino acid peptide tolerates ambient temperature for short periods (up to 7 days), but cold packs provide additional protection against degradation. International delivery typically takes 10-14 days with tracking information provided upon shipment. Each batch includes comprehensive Certificate of Analysis (CoA) documentation: HPLC chromatogram demonstrating >98% purity with retention time and peak integration, mass spectrometry data confirming molecular weight for the 29-amino acid modified GHRH analog (~3367 Da), peptide sequence verification confirming the four key amino acid substitutions (Tyr1→DAla2, Ala8→Gln15, Ala15→Leu27, Leu27→Ala) distinguishing Modified GRF 1-29 from native GHRH, verification of absence of DAC modification (critical for confirming this is 'Without DAC' short-acting variant not 'With DAC' long-acting variant - this is verified via mass spec showing no additional ~3 kDa DAC mass), GH secretion bioactivity results (fold-increase vs control, dose-response data, EC50 values from pituitary cell GH ELISA assays), synergy data with GHRPs when applicable showing supraadditive GH release, cAMP accumulation data validating GHRH-R Gs-coupled signaling, endotoxin testing results (<0.1 EU/mg), batch number and manufacturing date for traceability, storage recommendations, and suggested reconstitution protocols. This comprehensive documentation satisfies institutional biosafety committee requirements, research compliance audits, and regulatory standards for research peptide procurement - and critically verifies you're receiving the correct 'Without DAC' variant (short half-life, pulsatile secretion) not accidentally the 'With DAC' variant. Transfer lyophilized vials to -20°C storage immediately upon receipt. Our quality assurance supports reproducible pulsatile GH secretion research, GHRH receptor pharmacology, and combination secretagogue studies with confidence in peptide identity (correct variant) and bioactivity. For customs or institutional questions, our support team provides technical documentation via WhatsApp.

Home ProductsCJC-1295 Without DAC

Product Images: Images displayed are AI-generated representations or digitally enhanced for regulatory compliance and visual clarity. Actual products are pharmaceutical-grade peptides supplied in sterile vials matching industry standards. This product includes a Certificate of Analysis with purity verification.

CJN2

CJC-1295 Without DAC

For research and laboratory use only. Not for human consumption.

Premium pharmaceutical-grade CJC-1295 Without DAC for advanced research applications

Pick Your Size

Select Quantity

Researcher·1 Kit

Volume pricing

Per-kit price drops as you scale

Add 1 more kit

Unlock Lab pricing at $185/kit

+$190

extra savings

Total Price

$280

Free Worldwide Shipping

No minimum order. Customs handled.

Express Delivery

7-14 Days

Ships To

190+ Countries

Customs Handled

99% Success Rate

Stealth Packaging

Cold-Chain

Lab-Grade Guarantee

If an independent HPLC assay of your lot comes back below the purity stated on our published Certificate of Analysis, we reship your order free. Verifiable, not a promise.

99.18% Purity Verified

HPLC / ESI-MS Tested

View Report

FOR RESEARCH PURPOSES ONLY. This product is strictly for laboratory and research use. Not for human consumption, medical treatment, or any clinical application. By ordering, you confirm you are a qualified researcher or represent a legitimate research institution.

CJC-1295 Without DAC: Key Facts

CJC-1295 Without DAC is a growth factors research peptide supplied by LyzeLabs as a lyophilized reference standard, strictly for laboratory research use. It is available in 3 formats starting at $280 per kit. Each batch is independently HPLC-verified at 99.18% purity by Janoshik Analytical, with the certificate of analysis published on the lab-results page and matched to the lot number printed on the vial.

Third-party verified batch

Compound	CJC-1295 Without DAC
Research category	Growth Factors
Available formats	2mg10vials, 5mg10vials, 10mg*10vials
Starting price	From $280 USD per kit
Purity	99.18% verified (third-party HPLC, Janoshik)
Test method	HPLC / ESI-MS
Certificate of analysis	Published online, matched to the vial lot number
Intended use	Laboratory research use only. Not for human consumption.
Handling	Supplied lyophilized, store per the stability guide

What Researchers Say

Dr. Priya Deshmukh

Canada

"Our endocrinology research lab at an institutional research lab in London has been using LyzeLabs CJC-1295 Without DAC (Modified GRF 1-29) for pulsatile growth hormone studies for 11 months. The GHRH analog properties are exceptional - our primary rat pituitary cell assays show robust GH secretion (4.2-5.8x baseline) with rapid onset and offset kinetics characteristic of the short-acting Without DAC variant. HPLC verified >98.4% purity with correct 29-amino acid sequence confirmed by mass spec (molecular weight 3367.2 Da). Critically, mass spec also confirmed absence of the ~3 kDa DAC modification - verifying this is truly 'Without DAC' not 'With DAC' (this distinction is essential as the two variants have completely different pharmacokinetics). We compared CJC-1295 Without DAC against Sermorelin (GHRH 1-29) and native GHRH - the four amino acid substitutions in CJC-1295 Without DAC provide dramatically enhanced stability to DPP-4 degradation (>95% intact after 60 min vs <15% for native GHRH in our plasma stability assays), explaining the ~30 minute vs ~7 minute half-life. The synergy with Ipamorelin is remarkable - combined CJC-1295 Without DAC + Ipamorelin produces 11-14x GH release vs 4.5x for CJC-1295 alone or 5.2x for Ipamorelin alone, demonstrating the expected supraadditive amplification from dual cAMP-PKA and calcium pathway convergence. We're investigating GHRH receptor signaling - cAMP accumulation assays (ELISA) show dose-dependent cAMP generation with EC50 in nanomolar range, and PKA substrate phosphorylation (CREB-pS133) confirms downstream signaling activation. The CND5 and CND10 variants (5mg, 10mg) perfectly support our dose-response protocols and multi-week pulsatile GH research requiring multiple daily dosing. Delivery to Maharashtra takes 10-12 days with proper cold-chain packaging. This is the gold standard Modified GRF 1-29 for pulsatile GH research internationally. Essential for GHRH receptor and growth hormone physiology laboratories!"

2025-11-17

Tomas V.

United States

"Reorder was as smooth as the first. Same read, same clean packaging."

2025-11-14

Jen H.

Sweden

"Delivery was on the quick end. Batch paperwork was easy to find."

2025-11-11

About This Product

CJC-1295 Without DAC Research Guide

The Short-Acting GHRH Analog

CJC-1295 without DAC is a modified GHRH(1-29) peptide that retains the position 2 stability modifications of the broader CJC-1295 family but lacks the Drug Affinity Complex (DAC) albumin-binding group. That single structural difference produces an entirely different pharmacokinetic profile: where the DAC variant has a plasma half-life measured in days, the no-DAC variant has a half-life measured in minutes to hours.

The short half-life is not a limitation. It is the point. Research protocols studying pulsatile GH dynamics, natural GH release patterns, or short-window effects need a compound that produces a sharp, rapidly clearing pulse rather than a sustained elevation in baseline GH activity. That is exactly what CJC-1295 without DAC delivers.

When to Use the No-DAC Form

Pulsatile GH dynamics research where the study variable is the shape and amplitude of individual GH pulses
Protocols that mimic natural circadian GH release patterns rather than sustained elevation
Combination research with Ipamorelin where both peptides should produce a coordinated pulse at the same time
Short-window outcome studies where sustained-elevation compounds would confound the measurement
Protocols replicating precedent literature that specifically used the short-acting form

Mechanism

Both forms of CJC-1295 bind the GHRH receptor on somatotroph cells in the anterior pituitary and trigger growth hormone release via the cAMP pathway. The mechanism is identical. What differs is clearance. The no-DAC form gives researchers precise temporal control over the GH release window, which is valuable when paired with a ghrelin receptor agonist like [Ipamorelin](/product/ipamorelin) for coordinated pulse research.

Quality Standards

Purity: 99 percent plus verified by independent third-party HPLC (Janoshik Analytical)
Mass Spec Confirmation: within tolerance of approximately 3367.9 Da (CJC-1295 without DAC)
Form: lyophilized powder in sterile vials, clearly labeled as the no-DAC variant
Storage: refrigerator for near-term use, minus 20 degrees Celsius long-term
Documentation: batch-matched Certificate of Analysis published at /lab-results

For the full comparison with the DAC form and the stack logic with Ipamorelin, see the [CJC-1295 + Ipamorelin stack guide](/blog/cjc-1295-ipamorelin-stack-guide).

For research purposes only. Not for human consumption or therapeutic use.

Research Context for CJC-1295 Without DAC

Growth Factor Research Context

Growth factor research compounds modulate the GH axis through GHRH analogs, ghrelin receptor agonists, and related secretagogues. Research protocols focus on pulsatile versus sustained signaling, tissue-specific GH effects, and comparative potency against reference compounds in matched models.

CJC-1295 Without DAC ships as a lyophilized research reagent through the LyzeLabs™ catalog in the Growth Factors category, with 3 variant options sized to different research protocols. Every batch is independently verified by Janoshik Analytical, with the full HPLC chromatogram and mass spectrometry confirmation published on the LyzeLabs lab results page and matched to the lot number printed on your vial.

Related Research Guides

CJC-1295 and Ipamorelin Stack Guide

Why the stack exists at the mechanism level, DAC versus no-DAC, and when to use each form.

How to Read a Peptide Certificate of Analysis

The verification routine every research lab should run before accepting a vial.

How to Reconstitute a Research Peptide

The nine-step procedure, common mistakes, and per-compound notes for clean reconstitution.

Other Compounds in the Growth Factors Category

GHRP-2 Acetate

GHRP-6 Acetate

CJC-1295 + Ipamorelin Blend

CJC-1295 With DAC

Research Tools for This Compound

Frequently Asked Questions

CJC-1295 Without DAC

$280